Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 6,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $30.99, for a total value of $185,940.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of NASDAQ CDLX opened at $32.90 on Friday. The stock has a market capitalization of $618.63 million, a PE ratio of -15.37 and a beta of 1.76. Cardlytics Inc has a fifty-two week low of $9.80 and a fifty-two week high of $34.30. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.37 and a current ratio of 2.37. The company has a fifty day moving average of $27.77.
Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. The company had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. The firm’s quarterly revenue was up 37.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.21) earnings per share. Analysts predict that Cardlytics Inc will post -1.12 EPS for the current fiscal year.
A number of analysts have issued reports on the company. Raymond James raised their target price on Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. Zacks Investment Research cut Cardlytics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. ValuEngine cut Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. Bank of America reiterated a “buy” rating and issued a $32.00 price target (up from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. Finally, KeyCorp lifted their price target on Cardlytics from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $30.71.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can grew its position in shares of Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Cardlytics in the second quarter valued at $60,000. Rockefeller Capital Management L.P. purchased a new position in shares of Cardlytics in the second quarter valued at $85,000. Acadian Asset Management LLC bought a new stake in Cardlytics during the second quarter valued at $161,000. Finally, Gamco Investors INC. ET AL bought a new stake in Cardlytics during the first quarter valued at $256,000. Institutional investors own 71.09% of the company’s stock.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.